Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization - Total: 2015-2024

Historic Depreciation & Amortization - Total for Sunshine Biopharma (SBFM) over the last 7 years, with Dec 2024 value amounting to $146,518.

  • Sunshine Biopharma's Depreciation & Amortization - Total rose 48.27% to $95,821 in Q3 2025 from the same period last year, while for Sep 2025 it was $221,550, marking a year-over-year increase of 36.74%. This contributed to the annual value of $146,518 for FY2024, which is 32.35% up from last year.
  • As of FY2024, Sunshine Biopharma's Depreciation & Amortization - Total stood at $146,518, which was up 32.35% from $110,701 recorded in FY2023.
  • Sunshine Biopharma's 5-year Depreciation & Amortization - Total high stood at $146,518 for FY2024, and its period low was $12,741 during FY2021.
  • Moreover, its 3-year median value for Depreciation & Amortization - Total was $110,701 (2023), whereas its average is $92,620.
  • Its Depreciation & Amortization - Total has fluctuated over the past 5 years, first declined by 9.42% in 2021, then soared by 436.32% in 2023.
  • Sunshine Biopharma's Depreciation & Amortization - Total (Yearly) stood at $14,066 in 2020, then declined by 9.42% to $12,741 in 2021, then soared by 62.00% to $20,641 in 2022, then soared by 436.32% to $110,701 in 2023, then skyrocketed by 32.35% to $146,518 in 2024.